Cargando…

Evaluation of novel oral vaccine candidates and validation of a caprine model of Johne's disease

Johne's disease (JD) caused by Mycobacterium avium subspecies paratuberculosis (MAP) is a major threat to the dairy industry and possibly some cases of Crohn's disease in humans. A MAP vaccine that reduced of clinical disease and/or reduced fecal shedding would aid in the control of JD. Th...

Descripción completa

Detalles Bibliográficos
Autores principales: Hines, Murray E., Turnquist, Sue E., Ilha, Marcia R. S., Rajeev, Sreekumari, Jones, Arthur L., Whittington, Lisa, Bannantine, John P., Barletta, Raúl G., Gröhn, Yrjö T., Katani, Robab, Talaat, Adel M., Li, Lingling, Kapur, Vivek
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3941644/
https://www.ncbi.nlm.nih.gov/pubmed/24624365
http://dx.doi.org/10.3389/fcimb.2014.00026
_version_ 1782305957164875776
author Hines, Murray E.
Turnquist, Sue E.
Ilha, Marcia R. S.
Rajeev, Sreekumari
Jones, Arthur L.
Whittington, Lisa
Bannantine, John P.
Barletta, Raúl G.
Gröhn, Yrjö T.
Katani, Robab
Talaat, Adel M.
Li, Lingling
Kapur, Vivek
author_facet Hines, Murray E.
Turnquist, Sue E.
Ilha, Marcia R. S.
Rajeev, Sreekumari
Jones, Arthur L.
Whittington, Lisa
Bannantine, John P.
Barletta, Raúl G.
Gröhn, Yrjö T.
Katani, Robab
Talaat, Adel M.
Li, Lingling
Kapur, Vivek
author_sort Hines, Murray E.
collection PubMed
description Johne's disease (JD) caused by Mycobacterium avium subspecies paratuberculosis (MAP) is a major threat to the dairy industry and possibly some cases of Crohn's disease in humans. A MAP vaccine that reduced of clinical disease and/or reduced fecal shedding would aid in the control of JD. The objectives of this study were (1) to evaluate the efficacy of 5 attenuated strains of MAP as vaccine candidates compared to a commercial control vaccine using the protocol proposed by the Johne's Disease Integrated Program (JDIP) Animal Model Standardization Committee (AMSC), and (2) to validate the AMSC Johne's disease goat challenge model. Eighty goat kids were vaccinated orally twice at 8 and 10 weeks of age with an experimental vaccine or once subcutaneously at 8 weeks with Silirum® (Zoetis), or a sham control oral vaccine at 8 and 10 weeks. Kids were challenged orally with a total of approximately 1.44 × 10(9) CFU divided in two consecutive daily doses using MAP ATCC-700535 (K10-like bovine isolate). All kids were necropsied at 13 months post-challenge. Results indicated that the AMSC goat challenge model is a highly efficient and valid model for JD challenge studies. None of the experimental or control vaccines evaluated prevented MAP infection or eliminated fecal shedding, although the 329 vaccine lowered the incidence of infection, fecal shedding, tissue colonization and reduced lesion scores, but less than the control vaccine. Based on our results the relative performance ranking of the experimental live-attenuated vaccines evaluated, the 329 vaccine was the best performer, followed by the 318 vaccine, then 316 vaccine, 315 vaccine and finally the 319 vaccine was the worst performer. The subcutaneously injected control vaccine outperformed the orally-delivered mutant vaccine candidates. Two vaccines (329 and 318) do reduce presence of JD gross and microscopic lesions, slow progression of disease, and one vaccine (329) reduced fecal shedding and tissue colonization.
format Online
Article
Text
id pubmed-3941644
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-39416442014-03-12 Evaluation of novel oral vaccine candidates and validation of a caprine model of Johne's disease Hines, Murray E. Turnquist, Sue E. Ilha, Marcia R. S. Rajeev, Sreekumari Jones, Arthur L. Whittington, Lisa Bannantine, John P. Barletta, Raúl G. Gröhn, Yrjö T. Katani, Robab Talaat, Adel M. Li, Lingling Kapur, Vivek Front Cell Infect Microbiol Microbiology Johne's disease (JD) caused by Mycobacterium avium subspecies paratuberculosis (MAP) is a major threat to the dairy industry and possibly some cases of Crohn's disease in humans. A MAP vaccine that reduced of clinical disease and/or reduced fecal shedding would aid in the control of JD. The objectives of this study were (1) to evaluate the efficacy of 5 attenuated strains of MAP as vaccine candidates compared to a commercial control vaccine using the protocol proposed by the Johne's Disease Integrated Program (JDIP) Animal Model Standardization Committee (AMSC), and (2) to validate the AMSC Johne's disease goat challenge model. Eighty goat kids were vaccinated orally twice at 8 and 10 weeks of age with an experimental vaccine or once subcutaneously at 8 weeks with Silirum® (Zoetis), or a sham control oral vaccine at 8 and 10 weeks. Kids were challenged orally with a total of approximately 1.44 × 10(9) CFU divided in two consecutive daily doses using MAP ATCC-700535 (K10-like bovine isolate). All kids were necropsied at 13 months post-challenge. Results indicated that the AMSC goat challenge model is a highly efficient and valid model for JD challenge studies. None of the experimental or control vaccines evaluated prevented MAP infection or eliminated fecal shedding, although the 329 vaccine lowered the incidence of infection, fecal shedding, tissue colonization and reduced lesion scores, but less than the control vaccine. Based on our results the relative performance ranking of the experimental live-attenuated vaccines evaluated, the 329 vaccine was the best performer, followed by the 318 vaccine, then 316 vaccine, 315 vaccine and finally the 319 vaccine was the worst performer. The subcutaneously injected control vaccine outperformed the orally-delivered mutant vaccine candidates. Two vaccines (329 and 318) do reduce presence of JD gross and microscopic lesions, slow progression of disease, and one vaccine (329) reduced fecal shedding and tissue colonization. Frontiers Media S.A. 2014-03-04 /pmc/articles/PMC3941644/ /pubmed/24624365 http://dx.doi.org/10.3389/fcimb.2014.00026 Text en Copyright © 2014 Hines, Turnquist, Ilha, Rajeev, Jones, Whittington, Bannantine, Barletta, Gröhn, Katani, Talaat, Li and Kapur. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Microbiology
Hines, Murray E.
Turnquist, Sue E.
Ilha, Marcia R. S.
Rajeev, Sreekumari
Jones, Arthur L.
Whittington, Lisa
Bannantine, John P.
Barletta, Raúl G.
Gröhn, Yrjö T.
Katani, Robab
Talaat, Adel M.
Li, Lingling
Kapur, Vivek
Evaluation of novel oral vaccine candidates and validation of a caprine model of Johne's disease
title Evaluation of novel oral vaccine candidates and validation of a caprine model of Johne's disease
title_full Evaluation of novel oral vaccine candidates and validation of a caprine model of Johne's disease
title_fullStr Evaluation of novel oral vaccine candidates and validation of a caprine model of Johne's disease
title_full_unstemmed Evaluation of novel oral vaccine candidates and validation of a caprine model of Johne's disease
title_short Evaluation of novel oral vaccine candidates and validation of a caprine model of Johne's disease
title_sort evaluation of novel oral vaccine candidates and validation of a caprine model of johne's disease
topic Microbiology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3941644/
https://www.ncbi.nlm.nih.gov/pubmed/24624365
http://dx.doi.org/10.3389/fcimb.2014.00026
work_keys_str_mv AT hinesmurraye evaluationofnoveloralvaccinecandidatesandvalidationofacaprinemodelofjohnesdisease
AT turnquistsuee evaluationofnoveloralvaccinecandidatesandvalidationofacaprinemodelofjohnesdisease
AT ilhamarciars evaluationofnoveloralvaccinecandidatesandvalidationofacaprinemodelofjohnesdisease
AT rajeevsreekumari evaluationofnoveloralvaccinecandidatesandvalidationofacaprinemodelofjohnesdisease
AT jonesarthurl evaluationofnoveloralvaccinecandidatesandvalidationofacaprinemodelofjohnesdisease
AT whittingtonlisa evaluationofnoveloralvaccinecandidatesandvalidationofacaprinemodelofjohnesdisease
AT bannantinejohnp evaluationofnoveloralvaccinecandidatesandvalidationofacaprinemodelofjohnesdisease
AT barlettaraulg evaluationofnoveloralvaccinecandidatesandvalidationofacaprinemodelofjohnesdisease
AT grohnyrjot evaluationofnoveloralvaccinecandidatesandvalidationofacaprinemodelofjohnesdisease
AT katanirobab evaluationofnoveloralvaccinecandidatesandvalidationofacaprinemodelofjohnesdisease
AT talaatadelm evaluationofnoveloralvaccinecandidatesandvalidationofacaprinemodelofjohnesdisease
AT lilingling evaluationofnoveloralvaccinecandidatesandvalidationofacaprinemodelofjohnesdisease
AT kapurvivek evaluationofnoveloralvaccinecandidatesandvalidationofacaprinemodelofjohnesdisease